ArticleCase reports in oncology
A Rare Case of Tibiofemoral Ewing's Sarcoma Recurrence with Lung Metastasis 27 Years after Initial Diagnosis.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ewing's sarcoma (ES) is a rare, malignant small round-cell tumor. Some of the patients will experience local or distant recurrent illness. To detect early incidental or unexpected distant metastasis during the follow-up or initial evaluation, Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/computed tomography (PET-CT) plays a significant role and has the potential to impact clinical judgments as well as forecast the prognosis and resectability of ES patients. Case Presentation: We report the case of a 44-year-old patient who present a history of a treated ES located in left tibiofemoral articulation whom presented a recurrence and a metastatic tibiofemoral ES in the lung 27 years after his diagnosis and first management. Conclusion: Due to this risk of recurrence, ES needs a regular monitoring and follow-up. We propose a monitoring by 18F-FDG PET/CT-Scan once a year during 5 years then one time every 2 years to be able to detect early metabolic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.